logo_web
  • Clinical Trials
    • Management of medication
    • Management of reimbursement of expenses to patients
    • Supply of medical devices
    • Destruction
    • Calibration of medical devices
    • Import and labeling of medication
    • Masking. Placebos manufacturing
  • Blog
  • Quality
    • Certifications
    • RSE
  • Clients
  • Patient Reimbursement Forms
    • Validation / Expense Reimbursement Sheet
✕
  • Clinical Trials
    • Management of medication
    • Management of reimbursement of expenses to patients
    • Supply of medical devices
    • Destruction
    • Calibration of medical devices
    • Import and labeling of medication
    • Masking. Placebos manufacturing
  • Blog
  • Quality
    • Certifications
    • RSE
  • Clients
  • Patient Reimbursement Forms
    • Validation / Expense Reimbursement Sheet

Australia’s recipe for strengthening medical research capacity and leading the way into the next decade

At a time of great challenges in global health research, one of the countries with the most influence in this field is preparing a national strategy to shape the next ten years.

consalud.es

Health research presents challenges throughout the world. The search for more accurate and rapid diagnostic methods; for more innovative, more precise treatments; for monitoring systems; and for cures for diseases that currently have none involves large amounts of material and human resources that are difficult to obtain and maintain. Thus, not all countries can develop high-quality research that translates into solutions for patients. In fact, seven regions of the world provide most of the funding for research into diseases as common as cancer worldwide.

In recent years, research funding has been declining, with the shortage increasing following the United States’ announcement that it would be cutting a large part of its investment funds starting this year. At this point, it is time to strengthen national and international research with solutions that vary from country to country. Last week, Canadian experts pointed out that their country must prioritise long-term horizons, while other experts indicated that the European Union should continue to commit to more coordinated and synchronised funding. On Wednesday, Commissioner Ursula Von der Leyen called for global leadership in health by spearheading the new Global Health Resilience Initiative. this week Australia published the draft of its ten-year National Health Research Strategy, with other key points to address the sustainability problem that plagues every corner of the world in terms of medical research.

Australia is one of the world leaders in health research. According to a study published in The Lancet, it ranks fifth in global cancer research funding, behind only the United States, the European Union, the United Kingdom and Japan. It is also a member of the Commonwealth, one of the oldest and largest organisations (comprising 54 countries from different continents with historical ties to the United Kingdom), which acts as a counterweight to the United States, capable of making up for the American country’s lack of investment.

They want to build ‘a dynamic research system that benefits the nation.’

In the National Health and Medical Research Strategy 2026-2036, released for public consultation this week, the Australian Government seeks to ‘provide national direction and build on strengths in the health and medical research sector,’ as well as ‘fill any gaps and continue to attract researchers and investors.’ The ultimate goal: to improve health outcomes for the population.

THE AUSTRALIAN RECIPE

The draft Strategy, which has been released for public consultation, establishes five areas of focus for transforming research in the country. Firstly, they focus on building ‘a dynamic research system that benefits the nation’. How? By establishing and evaluating national priorities for investment; identifying future and emerging challenges for the health system; and prioritising collaboration and resource sharing through investment in platforms and networks across the medical and health research ecosystem.

The new research system also aims to increase the attractiveness of investment in this area by improving the relationship between research and industry processes and sharing risks. They will also strengthen local manufacturing capacity and the commercialisation of biotechnology and medical technology.

They will strengthen local manufacturing capacity and the commercialisation of biotechnology and medical technology.

This will prepare them to face future health challenges, such as health emergencies or pandemics, which will become increasingly common, as many experts have pointed out in the wake of the COVID-19 pandemic; the increase in ageing and its comorbidities and the rise in non-communicable diseases such as cancer, diabetes and obesity as a result of factors such as lifestyle; and the new technologies that are being integrated into health systems.

To adapt to this, Australians have focused on three points: leveraging innovative technologies and cutting-edge approaches such as artificial intelligence; taking a One Health approach to research by assessing its impact not only on human health but also on the environment, i.e. creating environmentally sustainable research; and strengthening strategic international collaborations, both globally and regionally. These measures can be extrapolated to other countries and aim to make Australia ‘a leader in the health research sector’, in the words of the Strategy’s head, Rosemary Huxtable.

Related entries

7 October, 2025

Spain consolidates its leadership in clinical trials with new guidelines promoting innovation, digitalisation and sustainability in hospital pharmacy


Leer más
2 October, 2025

Innovation and data at the service of clinical research


Leer más
30 September, 2025

Spain, European leader in clinical trials against cancer thanks to the agility and ‘atomisation’ of research groups


Leer más

Recent Posts

  • Spain consolidates its leadership in clinical trials with new guidelines promoting innovation, digitalisation and sustainability in hospital pharmacy
  • Innovation and data at the service of clinical research
  • Spain, European leader in clinical trials against cancer thanks to the agility and ‘atomisation’ of research groups
  • Advanced therapies in lymphoma: six years of CAR-T that have changed patients’ lives
  • The Community of Madrid aspires to become the “Silicon Valley” of the pharmaceutical sector.

Contacta con nosotros


Tfno: +34 955.77.67.67
Fax: +34 955.77.65.56
info@distefar.net


Distefar del Sur
Sede Central

Distefar del Sur S.L.
Av. Umbrete, 58,
41110 Bollullos de la Mitación, Sevilla

Sede Madrid

Calle de Zurbano, 45, 28010 Madrid

CENTRAL

Pol. PIBO. Avda. de Gines, 14
+34 955 776 767 /+34 692 454 913
41110 Bollullos de la Mitación (Sevilla)

MADRID DELEGATION

+34 674 575 115
28010 Madrid

Links of interest

  • Legal warning
  • Privacy policy
  • Cookies policy
  • Contact

© 2025 Distefar del Sur SL. All rights reserved. agencianodo.com

  • No translations available for this page
  • Contact
  • Private Zone
  • English

    [recaptcha]

    In accordance with the provisions of Regulation (EU) 2016/679 and Organic Law 3/2018 regarding Data Protection, we inform you that the data you provide in this form will be incorporated into a file owned by DISTEFAR DEL SUR, SL domiciled in the C / Umbrete 58, (Pol. Ind. Pibo), 41110 of Bollullos de la Mitación (Seville), in order to manage your request.

    In this regard, and if you wish to exercise your rights of access, rectification, cancellation, opposition, portability and limitation, please send a written communication to DISTEFAR DEL SUR, SL, to the address indicated above or to info@distefar.com, attaching copy of your National Identity Document or equivalent identification document.

    Basic information about Data Protection

     Epigraph

    Basic information Data Protection

    Responsable

    DISTEFAR DEL SUR, S.L.

    Purpose

    Process your inquiry / request
    Detailed information on Data Protection

    Legitimation

    Consent
    Detailed information on Data Protection

    Recipients

    It is not expected to carry out data communications to third parties, except legal obligation
    Transfers of data to third countries outside the European Union will not be carried out
    Detailed information on Data Protection

    Rights

    You have the right of access, rectification, deletion, portability of your data, as well as limitation or opposition to your treatment, as detailed in Detailed information on Data Protection

    Additional Information

    You can consult the additional and detailed information on data protection by clicking here Detailed information on Data Protection

    All the data requested / The fields marked with * in the form are mandatory, if not filled in DISTEFAR DEL SUR, S.L. will not be able to meet your request.